Denali Therapeutics Inc.
$20.54
▲
4.93%
2026-04-21 06:27:01
www.denalitherapeutics.com
NMS: DNLI
Explore Denali Therapeutics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.26 B
Current Price
$20.54
52W High / Low
$23.77 / $12.31
Stock P/E
—
Book Value
$6.49
Dividend Yield
—
ROCE
-53.07%
ROE
-45.69%
Face Value
—
EPS
$-2.96
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
503
Beta
1.1
Debt / Equity
4.17
Current Ratio
9.16
Quick Ratio
9.16
Forward P/E
-7.59
Price / Sales
—
Enterprise Value
$2.22 B
EV / EBITDA
-4.12
EV / Revenue
—
Rating
Strong Buy
Target Price
$36.21
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Jupiter Neurosciences, Inc. | $0.46 | — | $15.86 M | — | -73.72% | -7.39% | $3.33 / $0.31 | $0 |
| 2. | Eupraxia Pharmaceuticals Inc. | $7.2 | — | $599.04 M | — | -47.73% | -68.76% | $12.86 / $4.38 | $1.01 |
| 3. | Sionna Therapeutics, Inc. | $42.64 | — | $1.96 B | — | -28.32% | -31.79% | $46.46 / $9.24 | $6.86 |
| 4. | EyePoint, Inc. | $15.07 | — | $1.26 B | — | -74.45% | -72.19% | $19.11 / $5.3 | $3.7 |
| 5. | Telomir Pharmaceuticals, Inc. | $1.48 | — | $49.85 M | — | -178.22% | -3.18% | $3.1 / $1.05 | $0.17 |
| 6. | Aclaris Therapeutics, Inc. | $4.25 | — | $512.53 M | — | -53.3% | -50.2% | $4.89 / $1.08 | $0.85 |
| 7. | FibroBiologics, Inc. | $1.53 | — | $5.37 M | — | -211.82% | -4.19% | $30.6 / $1.03 | $1.85 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -137.37 M | -137.43 M | -134.96 M | -145.58 M | -129.85 M |
| Net Profit | -128.55 M | -126.9 M | -124.12 M | -132.97 M | -114.75 M |
| EPS in Rs | -0.81 | -0.8 | -0.78 | -0.84 | -0.72 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 330.53 M | 108.46 M |
| Operating Profit | -555.34 M | -501.88 M | -196.7 M | -340.74 M |
| Net Profit | -512.54 M | -422.77 M | -145.22 M | -325.99 M |
| EPS in Rs | -3.23 | -2.67 | -0.92 | -2.06 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.14 B | 1.37 B | 1.15 B | 1.46 B |
| Total Liabilities | 131.09 M | 144.5 M | 122.96 M | 417.81 M |
| Equity | 1.01 B | 1.23 B | 1.03 B | 1.04 B |
| Current Assets | 900.66 M | 864.44 M | 1.06 B | 1.37 B |
| Current Liabilities | 98.35 M | 102.21 M | 77.98 M | 363.92 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -412.6 M | -347.69 M | -357.99 M | -244.72 M |
| Investing CF | 255.28 M | -88.76 M | 249.31 M | -141.39 M |
| Financing CF | 189.22 M | 484.3 M | 17.82 M | 310.67 M |
| Free CF | -422.1 M | -363.61 M | -370.93 M | -262.55 M |
| Capex | -9.5 M | -15.91 M | -12.94 M | -17.83 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | 204.74% | — | — |
| Earnings Growth % | -191.12% | 55.45% | — | — |
| Profit Margin % | — | -43.94% | -300.56% | — |
| Operating Margin % | — | -59.51% | -314.16% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | -54.45% | -304.58% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.